Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petta

Showing results (591-600 of 736) with videos related to

Pageof 74
Sort By:
Reviews in Endocrine & Metabolic Disorders|May 6, 2026
Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)Roberto Vettor, Maria Letizia Petroni, Idit Dotan, et al.
Free Radical Biology & Medicine|October 27, 2018
Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulationDaniele Maria Lopes Pinheiro, Ana Helena Sales de Oliveira, Leonam Gomes Coutinho, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 7, 2019
Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severityStefania Di Mauro, Alessandra Scamporrino, Salvatore Petta, et al.
Journal of Hepatology|October 27, 2023
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver diseaseFederico Salomone, Rosaria Maria Pipitone, Miriam Longo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 22, 2020
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLDStefania Grimaudo, Stefano Bartesaghi, Raffaela Rametta, et al.
Scientific Reports|March 8, 2019
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver DiseaseSerena Pelusi, Guido Baselli, Alessandro Pietrelli, et al.
Journal of Viral Hepatitis|April 25, 2021
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohortVincenza Calvaruso, Salvatore Petta, Irene Cacciola, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, Marco Marzioni, Pierluigi Russo, et al.
Gastroenterology|July 24, 2012
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosisErica Villa, Calogero Cammà, Marco Marietta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2023
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver DiseaseChiara Rosso, Gian Paolo Caviglia, Giovanni Birolo, et al.
Pageof 74

Showing results (591-600 of 736) with videos related to

Sort By:
Pageof 74
Reviews in Endocrine & Metabolic Disorders|May 6, 2026
Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)Roberto Vettor, Maria Letizia Petroni, Idit Dotan, et al.
Free Radical Biology & Medicine|October 27, 2018
Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulationDaniele Maria Lopes Pinheiro, Ana Helena Sales de Oliveira, Leonam Gomes Coutinho, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 7, 2019
Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severityStefania Di Mauro, Alessandra Scamporrino, Salvatore Petta, et al.
Journal of Hepatology|October 27, 2023
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver diseaseFederico Salomone, Rosaria Maria Pipitone, Miriam Longo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 22, 2020
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLDStefania Grimaudo, Stefano Bartesaghi, Raffaela Rametta, et al.
Scientific Reports|March 8, 2019
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver DiseaseSerena Pelusi, Guido Baselli, Alessandro Pietrelli, et al.
Journal of Viral Hepatitis|April 25, 2021
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohortVincenza Calvaruso, Salvatore Petta, Irene Cacciola, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, Marco Marzioni, Pierluigi Russo, et al.
Gastroenterology|July 24, 2012
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosisErica Villa, Calogero Cammà, Marco Marietta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2023
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver DiseaseChiara Rosso, Gian Paolo Caviglia, Giovanni Birolo, et al.
Pageof 74